TNF and respiratory tract infectious disorder: Studies indicated that acitretin did not increase risk of viral or respiratory infections in psoriasis patients (49), and the rates of COVID-19 infection and hospitalization in psoriasis patients exposed to acitretin were similar to that of exposure to TNF inhibitors (34).